Literature DB >> 36118393

Prognostic Significance of C-reactive Protein/Albumin Ratio in Patients with Locally Advanced Unresectable Colorectal Cancer.

Masahide Ikeguchi1, Keigo Ashida2.   

Abstract

Despite the poor prognosis of unresectable colorectal cancer (CRC), some patients survive after intensive chemotherapy followed by complete resection of the primary and metastatic tumors. The pretreatment C-reactive protein/albumin ratio (CAR) is a significant prognostic indicator in various carcinomas. Therefore, in this retrospective study, we evaluated the prognostic significance of pretreatment CAR in patients with unresectable CRC. The 61 patients were diagnosed as having initially unresectable disease between January 2004 and December 2013. We analyzed the clinical courses of these patients. Blood samples were taken routinely at their first visit to our hospital. C-reactive protein (CRP), albumin (ALB), and carcinoembryonic antigen (CEA) were analyzed. The median survival time (MST) and 2-year overall survival (OS) of the patients was 9 months (range, 1-96 months) and 23%, respectively. The median CRP, ALB, CAR, and CEA levels of the patients were 2.2 mg/dL, 3.5 g/dL, 0.65, and 20.6 ng/mL, respectively. There was no correlation between CEA levels and the CAR. Patients were divided into two sub-groups using the median CAR level as the cut-off: high CAR (>0.65) and low CAR (≤0.65). Both MST and 2-year OS were significantly lower in the 30 high-CAR patients (4 months, 6.7%) than in the 31 low-CAR patients (13 months, 38.7%, p < 0.001). The primary tumors of three low-CAR patients could be removed after intensive chemotherapy. Thus, low-CAR patients with locally advanced CRC with or without distant metastasis may survive following intensive treatment, even if their tumors were previously deemed to be unresectable. © Indian Association of Surgical Oncology 2017.

Entities:  

Keywords:  Chemotherapy; Colorectal cancer; Conversion therapy; Inflammation; Prognosis

Year:  2017        PMID: 36118393      PMCID: PMC9478077          DOI: 10.1007/s13193-017-0639-0

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  12 in total

1.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Authors:  Jean-Yves Douillard; Salvatore Siena; James Cassidy; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; György Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean-Luc Canon; Mark Rother; Kelly S Oliner; Michael Wolf; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Low nutritional prognostic index correlates with poor survival in patients with stage IV colorectal cancer following palliative resection of the primary tumor.

Authors:  Kiyoshi Maeda; Masatsune Shibutani; Hiroshi Otani; Hisashi Nagahara; Kenji Sugano; Teturo Ikeya; Naoshi Kubo; Ryosuke Amano; Kenjiro Kimura; Kazuya Muguruma; Hiroaki Tanaka; Kosei Hirakawa
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

3.  Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus.

Authors:  Ines Gockel; Kathrin Dirksen; Claudia-M Messow; Theodor Junginger
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

4.  The prognostic nutritional index can be a prognostic indicator in colorectal carcinoma.

Authors:  Tadahiro Nozoe; Mayuko Kohno; Tomohiro Iguchi; Emiko Mori; Takashi Maeda; Akito Matsukuma; Takahiro Ezaki
Journal:  Surg Today       Date:  2011-12-03       Impact factor: 2.549

5.  Modified Glasgow prognostic score in patients with incurable stage IV colorectal cancer.

Authors:  Tomokazu Kishiki; Tadahiko Masaki; Hiroyoshi Matsuoka; Takaaki Kobayashi; Yutaka Suzuki; Nobutsugu Abe; Toshiyuki Mori; Masanori Sugiyama
Journal:  Am J Surg       Date:  2013-07-01       Impact factor: 2.565

6.  Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer.

Authors:  Kotaro Hirashima; Masayuki Watanabe; Hironobu Shigaki; Yu Imamura; Satoshi Ida; Masaaki Iwatsuki; Takatsugu Ishimoto; Shiro Iwagami; Yoshifumi Baba; Hideo Baba
Journal:  J Gastroenterol       Date:  2013-07-03       Impact factor: 7.527

7.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

8.  The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nami Imai; Akira Iwaku; Mutumi Oishi; Ken Tanaka; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Masato Matsushima
Journal:  Ann Surg Oncol       Date:  2014-09-05       Impact factor: 5.344

9.  Prognostic significance of preoperative C-reactive protein: albumin ratio in patients with clear cell renal cell carcinoma.

Authors:  Zhen Chen; Yingjie Shao; Min Fan; Qianfeng Zhuang; Kun Wang; Wei Cao; Xianlin Xu; Xiaozhou He
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

10.  Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.

Authors:  Jun-Eul Hwang; Ha-Na Kim; Dae-Eun Kim; Hyun-Jung Choi; Sung-Hoon Jung; Hyun-Jeong Shim; Woo-Kyun Bae; Eu-Chang Hwang; Sang-Hee Cho; Ik-Joo Chung
Journal:  BMC Cancer       Date:  2011-11-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.